M Risio

Summary

Affiliation: Institute for Cancer Research and Treatment
Country: Italy

Publications

  1. ncbi Reprint of: The natural history of adenomas
    Mauro Risio
    Unit of Pathology, Institute for Cancer Research and Treatment, Strada Provinciale 142, Km 3 95, 10060 Candiolo, Torino, Italy
    Best Pract Res Clin Anaesthesiol 24:397-406. 2010
  2. ncbi The natural history of adenomas
    Mauro Risio
    Institute for Cancer Research and Treatment, Candiolo, Torino, Italy
    Best Pract Res Clin Gastroenterol 24:271-80. 2010
  3. ncbi [Histopathologic diagnosis in colorectal cancer screening: guidelines]
    M Risio
    Servizio di Anatomia Patologica, IRCC, Candiolo, Torino
    Pathologica 98:171-4. 2006
  4. ncbi Programmed cell death, proliferating cell nuclear antigen and p53 expression in mouse colon mucosa during diet-induced tumorigenesis
    M Risio
    Department of Pathology, Institute for Cancer Research and Treatment, Candiolo Torino, Italy
    Anal Cell Pathol 21:87-94. 2000
  5. ncbi HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment
    Mauro Risio
    Unit of Pathology, Institute for Cancer Research and Treatment, Strada Provinciale 142, Km 3 95, I 10060 Candiolo, Torino, Italy
    Oncol Rep 13:305-9. 2005
  6. ncbi Deletions of 17p are associated with transition from early to advanced colorectal cancer
    Mauro Risio
    Unit of Pathology, Institute for Cancer Research and Treatment, Strada Provinciale 142, Km 3 95, 10060, Candiolo, Torino, Italy
    Cancer Genet Cytogenet 147:44-9. 2003
  7. ncbi HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples
    Mauro Risio
    Unit of Pathology, Institute for Cancer Research and Treatment, Candiolo Torino, Italy
    Int J Oncol 23:1381-7. 2003
  8. ncbi Serum bile acids, programmed cell death and cell proliferation in the mucosa of patients with colorectal adenomas
    M Fracchia
    Gastroenterology Unit, Institute for Cancer Research and Treatment--IRCC, Strada Provinciale N degree 142, Candiolo, Italy
    Dig Liver Dis 37:509-14. 2005
  9. ncbi Malignant adenoma: diagnosis, staging, risk factors, lymph node involvement and problems of sampling
    M Risio
    Unit of Pathology, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy
    Tech Coloproctol 8:s253-6. 2004
  10. ncbi Intermediate biomarkers in the colorectal tumor progression
    M Risio
    Centro Ricerche Neoplasie Apparato Digerente L. Novello Miglino, Ospedale San Giovanni Antica Sede, Torino, Italy
    Tumori 81:16-8. 1995

Collaborators

Detail Information

Publications36

  1. ncbi Reprint of: The natural history of adenomas
    Mauro Risio
    Unit of Pathology, Institute for Cancer Research and Treatment, Strada Provinciale 142, Km 3 95, 10060 Candiolo, Torino, Italy
    Best Pract Res Clin Anaesthesiol 24:397-406. 2010
    ..Knowledge of the biological machineries sustaining the progression rates and times could be crucial to refine the natural history assumptions in screening modelling...
  2. ncbi The natural history of adenomas
    Mauro Risio
    Institute for Cancer Research and Treatment, Candiolo, Torino, Italy
    Best Pract Res Clin Gastroenterol 24:271-80. 2010
    ..Knowledge of the biological machineries sustaining the progression rates and times could be crucial to refine the natural history assumptions in screening modelling...
  3. ncbi [Histopathologic diagnosis in colorectal cancer screening: guidelines]
    M Risio
    Servizio di Anatomia Patologica, IRCC, Candiolo, Torino
    Pathologica 98:171-4. 2006
  4. ncbi Programmed cell death, proliferating cell nuclear antigen and p53 expression in mouse colon mucosa during diet-induced tumorigenesis
    M Risio
    Department of Pathology, Institute for Cancer Research and Treatment, Candiolo Torino, Italy
    Anal Cell Pathol 21:87-94. 2000
    ..p53 protein was not immunohistochemically detected, suggesting that neither overexpression of wild-type nor mutated forms of the protein are involved in the above mentioned changes...
  5. ncbi HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment
    Mauro Risio
    Unit of Pathology, Institute for Cancer Research and Treatment, Strada Provinciale 142, Km 3 95, I 10060 Candiolo, Torino, Italy
    Oncol Rep 13:305-9. 2005
    ..Further studies on the imbalance between the amplified HER2 gene and functionally antagonist gene(s) on chromosome 17 are warranted...
  6. ncbi Deletions of 17p are associated with transition from early to advanced colorectal cancer
    Mauro Risio
    Unit of Pathology, Institute for Cancer Research and Treatment, Strada Provinciale 142, Km 3 95, 10060, Candiolo, Torino, Italy
    Cancer Genet Cytogenet 147:44-9. 2003
    ..01). These findings indicate that loss of genes from the 17p13.3 chromosome region may play an important role in sustaining the transition from early to advanced cancer in colorectal tumor progression...
  7. ncbi HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples
    Mauro Risio
    Unit of Pathology, Institute for Cancer Research and Treatment, Candiolo Torino, Italy
    Int J Oncol 23:1381-7. 2003
    ..1% for the years 2000, 1999, 1998, respectively; 0% for cases embedded during 1997. According to these results, the reliability of the FISH and immunohistochemical assays decreases after prolonged storage of paraffin-embedded specimens...
  8. ncbi Serum bile acids, programmed cell death and cell proliferation in the mucosa of patients with colorectal adenomas
    M Fracchia
    Gastroenterology Unit, Institute for Cancer Research and Treatment--IRCC, Strada Provinciale N degree 142, Candiolo, Italy
    Dig Liver Dis 37:509-14. 2005
    ....
  9. ncbi Malignant adenoma: diagnosis, staging, risk factors, lymph node involvement and problems of sampling
    M Risio
    Unit of Pathology, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy
    Tech Coloproctol 8:s253-6. 2004
    ....
  10. ncbi Intermediate biomarkers in the colorectal tumor progression
    M Risio
    Centro Ricerche Neoplasie Apparato Digerente L. Novello Miglino, Ospedale San Giovanni Antica Sede, Torino, Italy
    Tumori 81:16-8. 1995
    ..New "regression-related" biomarkers should be investigated for the planning of measures designed to bring about the regression of premalignant lesions...
  11. ncbi Specific K-ras2 mutations in human sporadic colorectal adenomas are associated with DNA near-diploid aneuploidy and inhibition of proliferation
    W Giaretti
    Laboratory of Biophysics Cytometry, National Institute for Cancer Research and Treatment, Candiolo, Genoa, Italy
    Am J Pathol 153:1201-9. 1998
    ..These data suggest that specific K-ras2 mutations in a subgroup of human sporadic colorectal adenomas play a role in chromosome instability and, contrary to expectations, are associated with inhibition of proliferation...
  12. ncbi Cytogenetic findings in a case of dedifferentiated chondrosarcoma
    Laura Casorzo
    Pathology Unit, Institute for Cancer Research and Treatment IRCC, Candiolo, Torino, Italy
    Cancer Genet Cytogenet 144:61-4. 2003
    ..A putative MFH tumor suppressor gene could be present in a critical region on chromosome bands 9p21~p22...
  13. ncbi Fluorescence in situ hybridization (FISH) evaluation of chromosomes 6, 7, 9 and 10 throughout human melanocytic tumorigenesis
    Laura Casorzo
    Unit of Pathology, Institute for Cancer Research and Treatment, Strada Provinciale 142, 10060 Candiolo-Torino, Italy
    Melanoma Res 15:155-60. 2005
    ....
  14. ncbi Bone marrow evaluation in small cell carcinoma of the lung
    G Giaccone
    Divisione di Oncologia Medica and Anatomia Patologica, Ospedale San Giovanni, Torino, Italy
    Acta Oncol 26:185-8. 1987
    ..In our experience bone marrow biopsy was of little value in staging SCLC. Bilateral biopsy plus aspirate, with the addition of more sophisticated staining techniques might, however, provide a higher yield of positive marrow involvement...
  15. ncbi High frequency of MYH gene mutations in a subset of patients with familial adenomatous polyposis
    Tiziana Venesio
    Unit of Pathology, Imnstitute for Cancer Research and Treatment, Candiolo Torino, Italy
    Gastroenterology 126:1681-5. 2004
    ..The aim of this study was to evaluate germline mutation frequencies of both MYH and APC susceptibility genes in Italian patients with attenuated familial adenomatous polyposis...
  16. ncbi Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab
    Giuliana Cavalloni
    Department of Medical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy
    Anticancer Drugs 19:689-96. 2008
    ..G-CSF treatment increases ErbB2 expression in vitro and in vivo enhancing the activity of trastuzumab on BC cell lines inducing apoptosis of BC cells with low or no ErbB2 genomic amplification...
  17. ncbi Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening
    Nereo Segnan
    CPO Piemonte, Torino, Italy
    Gastroenterology 132:2304-12. 2007
    ..We conducted a study to estimate population coverage and detection rate (DR) achievable through different strategies of colorectal cancer (CRC) screening...
  18. ncbi CD31 and CD34 expression as immunohistochemical markers of endothelial transdifferentiation in human cutaneous melanoma
    A M Pisacane
    Unit of Pathology, Institute for Cancer Research and Treatment, 10060 Candiolo, Torino, Italy
    Cell Oncol 29:59-66. 2007
    ....
  19. ncbi [Morphogenetic and molecular events in the early stages of colorectal carcinogenesis]
    M Risio
    Servizio di Anatomia ed Istologia Patologica, Istituto per la Ricerca e la Cura del Cancro, Candiolo, Torino, Italia
    Pathologica 97:178-9. 2005
  20. ncbi [Morphogenesis and molecular pathology of premalignant neoplastic lesions of the colon]
    M Risio
    Servizio di Anatomia ed Istrologia Patologica, Istituto per la Ricerca e Cura del Cancro, Candiolo, Torino
    Pathologica 95:282-3. 2003
  21. ncbi Germline APC mutation on the beta-catenin binding site is associated with a decreased apoptotic level in colorectal adenomas
    Tiziana Venesio
    Unit of Pathology, Institute for Cancer Research and Treatment (IRCC, Candiolo-Torino, Italy
    Mod Pathol 16:57-65. 2003
    ....
  22. ncbi Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice
    Andrea Casazza
    Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo, Italy
    J Clin Invest 120:2684-98. 2010
    ..In sum, Sema3E-Plexin D1 signaling in cancer cells is crucially implicated in their metastatic behavior and may therefore be a promising target for strategies aimed at blocking tumor metastasis...
  23. ncbi APC haploinsufficiency, but not CTNNB1 or CDH1 gene mutations, accounts for a fraction of familial adenomatous polyposis patients without APC truncating mutations
    Tiziana Venesio
    Unit of Pathology, Institute for Cancer Research and Treatment, Candiolo Torino, Genova, Italy
    Lab Invest 83:1859-66. 2003
    ..Our results support the notion that FAP/AAPC can result from APC constitutive haploinsufficiency, with gene deletion being a possible cause of reduced gene expression...
  24. ncbi An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice
    Massimiliano Mazzone
    Division of Molecular Oncology, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo, Italy
    J Clin Invest 114:1418-32. 2004
    ..These data show that proteolytic activation of pro-SF is a limiting step in tumor progression, thus suggesting a new strategy for the treatment or prevention of the malignant conversion of neoplastic lesions...
  25. ncbi Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates
    Nereo Segnan
    Centro Prevenzione Oncologica Regione Piemonte and Azienda Sanitaria Ospedaliera S Giovanni Battista, Torino, Italy
    J Natl Cancer Inst 97:347-57. 2005
    ..We compared the participation and detection rates achievable through different strategies of colorectal cancer screening...
  26. ncbi VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas
    Alberto M Pisacane
    Unit of Pathology, Institute for Cancer Research and Treatment, Strada Provinciale 142 km 3, 95, 10060 Candiolo, Torino, Italy
    Melanoma Res 15:39-43. 2005
    ..The role exerted by VEGF/VEGFR-2, however, seems to be independent of the development of a tumour-related capillary network...
  27. ncbi HER2 testing and correlation with efficacy of trastuzumab therapy
    Monica Fornier
    Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 16:1340-8, 1351-2; discussion 1352, 1355-8. 2002
    ..FISH is not as widely available and is more costly than immunohistochemistry, but economic modeling shows that it is the most effective (and cost-effective) option...
  28. ncbi Near-diploid and near-triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status
    Walter Giaretti
    National Institute for Cancer Research, Genoa, Italy
    Genes Chromosomes Cancer 37:207-13. 2003
    ..We suggest that DNA near-diploid and near-triploid subpopulations in human sporadic CRC reflect different genetic mechanisms of CIN and have a potentially different clinical behavior...
  29. ncbi Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis
    Cesare Hassan
    Department of Gastroenterology and Digestive Endoscopy, Nuovo Regina Margherita Hospital, Rome, Italy
    Dis Colon Rectum 48:1588-96. 2005
    ..8 percent. CONCLUSIONS: All three histologic risk factors are significantly associated with the clinical outcome. Classification in low-risk and high-risk patients may be regarded as a meaningful staging procedure...
  30. ncbi Constitutional high expression of an APC mRNA isoform in a subset of attenuated familial adenomatous polyposis patients
    Tiziana Venesio
    Unit of Pathology, Institute for Cancer Research and Treatment IRCC, Strada Provinciale 142, 10060, Candiolo, Torino, Italy
    J Mol Med (Berl) 85:305-12. 2007
    ..Although functional data are required, the isoform we observed might have some pathogenic role, accounting for the heterogeneous phenotype that characterizes the polyposis syndrome...
  31. ncbi KRAS transitions and villous growth in colorectal adenomas
    Mauro Risio
    Cell Oncol 27:363-6. 2005
  32. ncbi Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer
    Elio Geido
    Laboratorio di Biofisica e Citometria, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Cytometry 50:216-24. 2002
    ..5 with k-ras2 mutations and above 3 with the G-->C/T transversions. CONCLUSION: Combined FCM and k-ras2 analysis may be used to predict long-term increased risk of death in sCRC patients...
  33. ncbi Chromosomal instability and APC gene mutations in human sporadic colorectal adenomas
    Walter Giaretti
    Department of Oncogenesis, National Institute for Cancer Research, Genoa, Italy
    J Pathol 204:193-9. 2004
    ....
  34. ncbi Immunohistochemical expression of MYH protein can be used to identify patients with MYH-associated polyposis
    Carmela Di Gregorio
    Division of Pathology, Hospital of Carpi, Modena, Italy
    Gastroenterology 131:439-44. 2006
    ..We investigated the expression pattern of the MYH protein to evaluate whether a immunohistochemical approach could be used in clinical practice to screen patients for germline mutations in the MYH gene...
  35. ncbi Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases
    Jean Nicolas Vauthey
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 24:2065-72. 2006
    ..Chemotherapy before resection of hepatic colorectal metastases (CRM) may cause hepatic injury and affect postoperative outcome...
  36. ncbi Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE
    Nereo Segnan
    Unit of Epidemiology, Centro per la Prevenzione Oncologica Piemonte, Azienda Sanitaria Ospedaliero S Giovanni Batista, Via S Francesco da Paola 31, Piemonte, 10123 Turin, Italy
    J Natl Cancer Inst 94:1763-72. 2002
    ..We present the baseline screening outcomes...